Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
复制标题
对多重人类免疫缺陷病毒-1、丙型肝炎病毒和乙型肝炎病毒核酸检测测定法进行评估，以检测泰国北部的病毒血症献血者。
DOI：
10.1111/j.1537-2995.2007.01395.x
复制
发表时间：
2007
期刊：
影响因子：
2.9
通讯作者：
Nelson,KenradE
中科院分区：
文献类型：
--
作者：
Nantachit,Niwes;Thaikruea,Lakkana;Thongsawat,Satawat;Leetrakool,Nipapan;Fongsatikul,Ladda;Sompan,Prakai;Fong,Yiu-Lian;Nichols,David;Ziermann,Rainer;Ness,Paul;Nelson,KenradE
背景：美国最近开始通过核酸检测（NAT）对献血者进行人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）筛查。然而，关于感染率较高的亚洲发展中国家捐助者额外 NAT 产量的数据有限。此外，高流行地区乙型肝炎病毒（HBV）NAT的数据很少。 研究设计和方法：使用市售的NAT检测（Procleix Ultrio，Gen-Probe, Inc.）对泰国清迈大学医院血库的总共5083名全血捐献者进行评估，以筛查个人献血。结果：没有发现HIV-1或HCV的NAT产量病例。然而，有 17 个样本的 HBV DNA NAT 和乙型肝炎表面抗原 (HBsAg) 检测结果存在差异。其中 7 例为 HBV DNA NAT 阳性、HBsAg 阴性；这 7 人中，1 人在基线时为 NAT 阳性，但随访时为阴性，并被认为是假阳性，1 人患有急性感染，5 人患有慢性流行 HBV 感染，4798 名 HBsAg 阴性供体中的 NAT 产量为 6 (1:800)。此外，还有 10 份 NAT 阴性、HBsAg 阳性的血清样本。所有患者均为抗乙型肝炎核心抗原免疫球蛋白 G 阳性；在使用更灵敏的 NAT 目标捕获测定进行测试时，5 例呈阳性 (1.8-20.6 IU/mL)，5 例呈阴性。结论：在泰国北部对个体供者血清样本进行多重 NAT 筛查，每 800 名 HBV NAT 阳性、HBsAg 阴性供者中大约检测到 1 名。泰国和其他亚洲国家的 HBV 感染率特别高，这表明对捐献者进行 HBV NAT 筛查将比其他地区更具成本效益。
BACKGROUND:Screening of blood donors with nucleic acid testing (NAT) for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) has been implemented recently in the United States. There are limited data, however, on the additional NAT yield of donors in developing countries in Asia where the prevalence of infection is higher. In addition, data on hepatitis B virus (HBV) NAT in high prevalence areas are minimal.STUDY DESIGN AND METHODS:A total of 5083 whole‐blood donors at the Chiang Mai University Hospital, Thailand, blood bank were evaluated with a commercially available NAT assay (Procleix Ultrio, Gen‐Probe, Inc.) to screen individual donations.RESULTS:No NAT yield cases were found for HIV‐1 or HCV. There were 17 samples with discrepant HBV DNA NAT and hepatitis B surface antigen (HBsAg) tests, however. Seven of these were HBV DNA NAT–positive, HBsAg‐negative; of these 7, 1 was NAT‐positive at baseline, but negative on follow‐up, and considered a false‐positive, 1 had an acute infection, and 5 had chronic prevalent HBV infections, for a NAT yield of 6 in 4798 HBsAg negative donors (1:800). In addition there were 10 NAT‐negative, HBsAg‐positive serum samples. All were anti‐hepatitis B core antigen immunoglobulin G–positive; on testing with a more sensitive NAT target capture assay, 5 were positive (1.8‐20.6 IU/mL) and 5 were negative.CONCLUSION:Multiplex NAT screening of individual‐donor serum samples in Northern Thailand detected approximately 1 per 800 HBV NAT–positive, HBsAg‐negative donors. The especially high prevalence of HBV infection in Thailand and other Asian countries suggests that HBV NAT screening of donors will be more cost‐effective than in other areas.